FeesSafety
Pluang+

HTX launches MSCI/USDT perpetual contract with up to 20x leverage for long and short trading.

Market News
03 Nov 2026, 12:01 WIB
Tokenpost
View Source
Neutral
HTX launches MSCI/USDT perpetual contract with up to 20x leverage for long and short trading.

HTX introduced a new MSCI/USDT perpetual contract on November 3, allowing traders to take long or short positions with leverage ranging from 1x to 20x. This addition expands HTX's derivatives market, providing more options for investors to speculate on MSCI movements with significant leverage. The contract supports continuous trading without expiry, enhancing flexibility for market participants. This launch marks a notable expansion in HTX's offerings in the digital asset derivatives space.

HTX's launch of the MSCI/USDT perpetual contract is the subject, with Pluang market data as context for readers. As of Nov 03, 2026 16:41 WIB, out of 50 major cryptocurrencies priced on Pluang, 7 rose and 42 fell. Notable movers include CAKE at Rp32.995 with a 1-day change of -5.52% and a Pluang order activity of 92% Sell / 8% Buy, BAT at Rp2.275 with -5.08% change and 5% Sell / 95% Buy activity, and MANA at Rp1.285 with -4.32% change and 98% Sell / 2% Buy activity. The most notable figure is CAKE's 92% sell order activity.

More News

Anavex names Terrie Kellmeyer CEO to lead clinical growth and FDA engagement

Anavex names Terrie Kellmeyer CEO to lead clinical growth and FDA engagement

Anavex Life Sciences appointed Terrie Kellmeyer, Ph.D., as President and CEO, also joining the Board. Kellmeyer, with over 30 years in biopharma, has led the company through key clinical milestones including FDA clearance for Fragile X syndrome trial...

Company Fundamentals
Bullish
1 hour ago
Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026

Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026

Cardiff Oncology, a clinical-stage biotech company focusing on cancer therapies via PLK1 inhibition, announced it will present at the UBS Global Biopharma Conference on November 16-17, 2026. The company's CEO, Mani Mohindru, will deliver a fireside c...

Market News
Bullish
1 hour ago
Seyond expands smart city tech with LiDAR-powered operational twins and AI collaborations

Seyond expands smart city tech with LiDAR-powered operational twins and AI collaborations

Seyond Inc is enhancing its smart city solutions by integrating advanced LiDAR 3D sensing with AI-powered analytics and collaborations with Dell Technologies, NVIDIA, and AMSYS. This expansion supports improved safety, transportation, and infrastruct...

Market News
Bullish
1 hour ago
Stella-Jones schedules Q3 2026 earnings call for Nov 4, open to investors and analysts.

Stella-Jones schedules Q3 2026 earnings call for Nov 4, open to investors and analysts.

Stella-Jones Inc. announced a teleconference on November 4, 2026, at 10:00 AM EST to discuss its third-quarter 2026 financial results. The event is open to investors, analysts, and interested parties, with live streaming and phone access provided. A ...

Company Fundamentals
Neutral
2 hours ago
Stella-Jones to hold Q3 2026 financial results conference call on Nov 4

Stella-Jones to hold Q3 2026 financial results conference call on Nov 4

Stella-Jones Inc. announced a conference call for November 4, 2026, at 10:00 AM EST to discuss its third quarter 2026 financial results. The call is open to investors, analysts, and interested parties and will be webcast live with a recording availab...

Company Fundamentals
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App